eClinical Tech News

TG Therapeutics will showcase new BRIUMVI (ublituximab-xiiy) data at AAN 2026 in Chicago, including the first Phase 4 real-world...

Ataibeckley has cleared a key regulatory hurdle for its lead program in treatment-resistant depression, securing FDA alignment at end-of-Phase...

Atea Pharmaceuticals has completed enrollment of its North American phase 3 C-BEYOND trial evaluating the fixed-dose combination of bemnifosbuvir...

Metagenomi Therapeutics (Nasdaq: MGX) reported full-year 2025 results, unveiled a corporate rebrand, and detailed clinical readiness steps for its...

Camp4 Therapeutics reported full-year 2025 results, advanced its lead SYNGAP1 program toward first-in-human testing, secured a discovery-stage collaboration with...

BridgeBio Oncology Therapeutics reported fourth‑quarter and full‑year 2025 results and, more importantly for the market, unveiled early clinical signals...

aTyr Pharma will meet the FDA in mid-April 2026 to review mixed Phase 3 results for efzofitimod in pulmonary...

Kuva Labs has signed a definitive agreement to acquire Lisata Therapeutics via a tender offer at $5.00 per share...

Kamada will report fourth-quarter and full-year 2025 results on March 11, 2026, and host an investor call that morning....

AnaptysBio will separate its business into two public companies in the second quarter of 2026, potentially as early as...